Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dorgenmeltucel-L - Lumos Pharma

Drug Profile

Dorgenmeltucel-L - Lumos Pharma

Alternative Names: HyperAcute Melanoma; Melanoma immunotherapy - Lumos Pharma; NLG-12036

Latest Information Update: 27 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NewLink Genetics Corporation
  • Developer Lumos Pharma; NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 07 Aug 2015 Dorgenmeltucel-L is still in phase II trials for Malignant melanoma in the USA
  • 25 Feb 2014 NewLink Genetics Corporation plans a phase IIb trial for Malignant melanoma in USA (NCT02054520)
  • 01 Jun 2012 Final efficacy, immunogenicity and adverse events data from a phase II trial in Malignant melanoma presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top